FAQ Library

FAQ Library published on November 8, 2016
Join Dr. Stadtmauer as he explains how to define and measure minimal residual disease (MRD) in patients with multiple myeloma, as well as the clinical implications of this technique to patient care.
FAQ Library published on November 3, 2016
Join Dr. Richter as he discusses the difference between smoldering myeloma and symptomatic multiple myeloma, and emerging criteria to classify and treat the former.
FAQ Library published on October 11, 2016
Join Dr. Giralt as he explains whether or not you should wait for the development of CRAB before initiating therapy for your multiple myeloma patients.
FAQ Library published on October 7, 2016
Join Dr. Landgren as he discusses the relative value of multicolor flow cytometry in an assessment for minimal residual disease (MRD) in multiple myeloma, compared to allele-specific PCR.
FAQ Library published on September 27, 2016
Join Dr. Orlowski as he discusses how to select between carfilzomib and ixazomib as a proteosome inhibitor, especially in the relapsed or refractory setting.
FAQ Library published on September 14, 2016
Join Dr. Richter as he explains the clinical significance of minimal residual disease (MRD) testing in multiple myeloma.
FAQ Library published on September 8, 2016
Join Dr. Orlowski as he explains how he decides between using a doublet or a triplet salvage regimen for his multiple myeloma patients.
FAQ Library published on August 18, 2016
Join Dr. Lonial as he explains how the new International Myeloma Working Group definition of active multiple myeloma will affect clinical practice.
FAQ Library published on August 11, 2016
Join Dr. Landgren as he explains how immunotherapeutic agents and monoclonal antibodies fit into the real-world treatment of patients with multiple myeloma.
FAQ Library published on August 3, 2016
Join Dr. Giralt as he explains the new recommended baseline workup tests for multiple myeloma.
Page 3 of 13
Results 21 - 30 of 122